Fibryga
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Fibryga
- Generic name
- FIBRINOGEN (HUMAN)
- Manufacturer
- Octapharma USA Inc
- Product type
- PLASMA DERIVATIVE
- SPL set ID
- 007a93f4-d84b-1fa9-51ed-32f6140bf423
- SPL ID
- 6992507e-97be-76ce-a0dc-902d94433f9b
- Version
- 13
- Effective date
- 2024-07-31
- Source export date
- 2026-11-13
- Source partition
- 11
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0011-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/0ccebc9befe0ec22afe916211b2687f6eef8ed163963720f103786a7f2d2e3ae/drug-label-0011-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 17:32:51
| Harmonized routes |
|---|
| INTRAVENOUS |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | BLA | 125612 | derived:openfda.application_number |
| application number | BLA125612 | openfda.application_number | |
| brand name | Fibryga | openfda.brand_name | |
| generic name | FIBRINOGEN (HUMAN) | openfda.generic_name | |
| manufacturer name | Octapharma USA Inc | openfda.manufacturer_name | |
| ndc | package | 68982-347-01 | openfda.package_ndc |
| ndc | package | 68982-348-01 | openfda.package_ndc |
| ndc | product | 68982-347 | openfda.product_ndc |
| ndc11 | package | 68982034801 | derived:openfda.package_ndc |
| ndc11 | package | 68982034701 | derived:openfda.package_ndc |
| rxcui | 831506 | openfda.rxcui | |
| rxcui | 1947382 | openfda.rxcui | |
| spl id | 6992507e-97be-76ce-a0dc-902d94433f9b | id | |
| spl set id | 007a93f4-d84b-1fa9-51ed-32f6140bf423 | set_id |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS Monitor patients for early signs of hypersensitivity or allergic reactions. If necessary, discontinue administration and institute appropriate treatment ( 5.1 ). Thrombotic events have been reported in patients receiving FIBRYGA. Treatment with human fibrinogen concentrate has been associated with thrombosis at target plasma fibrinogen levels that were below 150 mg/dL. The thrombotic risks may be greater when the target fibrinogen plasma level is 150 mg/dL. Weigh the benefits of administration versus the risks of thrombosis ( 5.2 ). FIBRYGA is made from pooled human plasma. Products made from human plasma may contain infectious agents, e.g., viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent ( 5.3 ). 5.1 Hypersensitivity Reactions Hypersensitivity reactions may occur. If early signs of hypersensitivity reactions (including hives, generalized urticaria, tightness of the chest, wheezing, hypotension, and anaphylaxis) or symptoms of allergic reactions occur, immediately discontinue administration [see Patient Counseling Information ( 17 )] . The treatment required depends on the nature and severity of the reaction. 5.2 Thrombosis Thrombosis may occur spontaneously in patients with acquired or congenital fibrinogen deficiency with or without the use of fibrinogen replacement therapy. Thrombotic events have been reported in patients receiving FIBRYGA. In the FIBRES study, there were 32 patients (8.6%) in the FIBRYGA group who experienced a total of 37 thromboembolic adverse events: cerebrovascular accident (n=17 events); intestinal ischemia (n=4); deep vein thrombosis (n=3); myocardial infarction (n=3); peripheral ischemia (n=2); pulmonary embolism (n=3); transient ischemic attack (n=1); cardiac arrest (n=1); disseminated intravascular coagulation (n=1); ischemic hepatitis (n=1); and thrombophlebitis (n=1). In the cryoprecipitate group, 45 patients (12.4%) experienced a total of 50 thromboembolic adverse events: cerebrovascular accident (n =18 events); venous thrombosis (n=13); cardiac arrest (n=4); myocardial infarction (n=4); intestinal ischemia (n=3); transient ischemic attack (n=1); amaurosis fugax (n=1); aortic thrombosis (n=1); medullar ischemia (n=1); optic ischemic neuropathy (n=1); peripheral artery occlusion (n=1); peripheral ischemia (n=1); and vascular graft occlusion (n=1). Treatment with human fibrinogen concentrate in congenital fibrinogen deficiency has been associated with risk of thrombosis at target fibrinogen levels that were less than 150 mg/dL. The risk of thrombosis may be greater when the target fibrinogen plasma level is 150 mg/dL. Weigh the benefits of FIBRYGA administration versus the risks of thrombosis. Patients receiving FIBRYGA should be monitored for signs and symptoms of thrombosis. [see Patient Counseling Information ( 17 )] 5.3 Transmissible Infectious Agents FIBRYGA is made from human plasma. Products made from human plasma may contain infectious agents (e.g., viruses and the CJD agent that can cause disease). Also, unknown infectious agents may be present in such products [see Patient Counseling Information ( 17 )] . The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus infections, and by a process demonstrated to inactivate and/or remove certain viruses during manufacturing [see Description ( 11 )] . Despite these measures, such products may transmit disease. All infections thought by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to Octapharma at 1-866-766-4860.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The most serious adverse reactions that may be observed with FIBRYGA are thromboembolic episodes and anaphylactic-type reactions. The most common adverse reactions observed in clinical studies with FIBRYGA in acquired fibrinogen deficiency (> 5% of patients) were abnormal hepatic function, acute kidney injury, anemia, atrial fibrillation, delirium and renal failure ( 6 ). The most common adverse reactions observed in clinical studies with FIBRYGA in congenital fibrinogen deficiency (> 5% of patients) were nausea, vomiting, pyrexia (fever), and thrombocytosis ( 6 ). To report SUSPECTED ADVERSE REACTIONS, contact Octapharma at 1-866-766-4860 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rate in the clinical trials of another drug and may not reflect the rates observed in practice. Four hundred twenty-eight patients received at least one dose of FIBRYGA for the treatment of bleeding and/or for perioperative management. In total, 677 doses were infused in five studies [ 1 - 5 ]. The safety of FIBRYGA was investigated in FIBRES, a randomized controlled trial comparing FIBRYGA to cryoprecipitate in adult patients with acquired fibrinogen deficiency who were experiencing clinically significant bleeding and hypofibrinogenemia after cardiac surgery [ 1 ]. In total, 1296 adverse events occurred in 512 patients during the study after receipt of fibrinogen supplementation: 623 events in 248 (66.7%) patients in the FIBRYGA group, and 673 events in 264 (72.7%) patients in the cryoprecipitate group. Deaths A total of 35 (9.41%) patients died in the period up to postoperative day 28 in the FIBRYGA group and 27 (7.44%) patients died in the cryoprecipitate group. After postoperative day 28, an additional 5 patients died after receiving FIBRYGA and an additional 2 patients died after receiving cryoprecipitate. Adverse Events Serious adverse reactions occurred in 117 (31.5%) patients in the FIBRYGA group compared to 126 (34.7%) patients in the cryoprecipitate group. The most common adverse reactions are shown in Table 1. Table 1: Adverse Reactions Reported in More Than 5% of Patients Following FIBRYGA or Cryoprecipitate Administration in the FIBRES Study FIBRYGA Patients (N=372) n (%) Cryoprecipitate Patients (N=363) n (%) Cardiac disorders Atrial fibrillation 108 (29.0%) 122 (33.6%) Blood and lymphatic system disorders Anemia 58 (15.6%) 52 (14.3%) Thrombocytopenia 15 (4.0%) 20 (5.5%) Psychiatric disorders Delirium 56 (15.1%) 54 (14.9%) Renal and urinary disorders Acute kidney injury 29 (7.8%) 29 (8.0%) Renal failure 19 (5.1%) 19 (5.2%) Hepatobiliary disorders Hepatic function abnormal 27 (7.3%) 26 (7.2%) Infections and infestations Pneumonia 18 (4.8%) 19 (5.2%) In the congenital fibrinogen deficiency studies [ 3 - 5 ], one patient had a mild skin reaction (itchiness and redness) after FIBRYGA administration for a bleeding episode and was treated with diphenhydramine and hydrocortisone. Thereafter, the patient received another infusion of FIBRYGA for the treatment of the same bleeding episode and another FIBRYGA infusion for surgical management during the next week. For both of those FIBRYGA infusions the patient was treated with diphenhydramine and hydrocortisone prophylactically and did not experience any drug reactions. Further adverse reactions included one case each of digital foot ischemia, portal vein thrombosis following splenectomy, and peripheral phlebitis of the upper limbs. The following serious adverse reactions are described elsewhere in the labeling: Hypersensitivity reactions [see Warnings and Precautions ( 5.1 )] Thrombosis risk [see Warning and Precautions ( 5.2 )] Possible transmission of infectious agents [see Warnings and Precautions ( 5.3 )]
adverse reactions table
<table><thead><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"/><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"> FIBRYGA Patients (N=372) </content> <content styleCode="bold"> n (%)</content></td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"> Cryoprecipitate Patients (N=363) </content> <content styleCode="bold"> n (%)</content></td></tr></thead><tbody><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule"><content styleCode="bold"> Cardiac disorders</content></td><td align="left" valign="top" styleCode="Toprule Botrule"/><td align="left" valign="top" styleCode="Toprule Botrule Rrule"/></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Atrial fibrillation</td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 108 (29.0%)</td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 122 (33.6%)</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule"><content styleCode="bold"> Blood and lymphatic system disorders</content></td><td align="left" valign="top" styleCode="Toprule Botrule"/><td align="left" valign="top" styleCode="Toprule Botrule Rrule"/></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Anemia</td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 58 (15.6%)</td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 52 (14.3%)</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Thrombocytopenia</td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 15 (4.0%)</td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 20 (5.5%)</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule"><content styleCode="bold"> Psychiatric disorders</content></td><td align="left" valign="top" styleCode="Toprule Botrule"/><td align="left" valign="top" styleCode="Toprule Botrule Rrule"/></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Delirium</td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 56 (15.1%)</td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 54 (14.9%)</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule"><content styleCode="bold"> Renal and urinary disorders</content></td><td align="left" valign="top" styleCode="Toprule Botrule"/><td align="left" valign="top" styleCode="Toprule Botrule Rrule"/></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Acute kidney injury</td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 29 (7.8%)</td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 29 (8.0%)</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Renal failure</td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 19 (5.1%)</td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 19 (5.2%)</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule"><content styleCode="bold"> Hepatobiliary disorders</content></td><td align="left" valign="top" styleCode="Toprule Botrule"/><td align="left" valign="top" styleCode="Toprule Botrule Rrule"/></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Hepatic function abnormal</td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 27 (7.3%)</td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 26 (7.2%)</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule"><content styleCode="bold"> Infections and infestations</content></td><td align="left" valign="top" styleCode="Toprule Botrule"/><td align="left" valign="top" styleCode="Toprule Botrule Rrule"/></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Pneumonia</td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 18 (4.8%)</td><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 19 (5.2%)</td></tr></tbody></table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.